ArticleCancer reports (Hoboken, N.J.)2024
Validity and Reliability of the Amharic Version of EORTC QLQ-OG25 Among Esophagogastric Cancer Patients in Ethiopia.
Article in Cancer reports (Hoboken, N.J.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Health-related quality of life in esophageal cancer: a state-of-the-art review of patient-reported outcomes and an evidence and gap map.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2025Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundCancers of the stomach and esophagus are the fourth and sixth most common causes of cancer-related deaths worldwide, respectively. Although various tools have been developed to assess the quality of life of patients with esophagogastric cancer, EORTC QLQ-C30 and EORTC QLQ-OG25 are the most used all over the world. However, they have not been validated in an Ethiopian context. Therefore, this study aimed to evaluate the psychometric properties of EORTC QLQ-OG25 among Ethiopian patients with esophageal and gastric cancer.
methodsEORTC QLQ-OG25 is a 25-item tool with 10 single items and six symptom scales: Eating restrictions, reflux, dysphagia, odynophagia, discomfort and pain, and anxiety. The tool was translated into Amharic according to the EORTC forward-backward translation protocol. To check its validity and reliability, a cross-sectional study among 158 patients was conducted from March to May 2020 at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia. The psychometric properties of EORTC QLQ-C30 and EORTC QLQ-OG25 were assessed using multitrait scale analysis, known group validity, convergent validity, and divergent validity. Internal consistency was examined with Cronbach's alpha.
resultEighty-three (52.5%) of the participants were men; the median age was 50 years (IQR = 18 years). The overall item correlation alpha values ranged between 0.39 and 0.7. All item correlations within their scales were greater than 0.4. The correlation coefficients between all items and their own domain were greater than for other domains. The esophagogastric and core questionnaire correlation ranged from -0.65 to 0.62. The tool showed a significant difference between patients with good physical function and those with impaired physical function.
conclusionsThe findings suggest that the Amharic version of EORTC QLQ-OG25 is a valid and reliable tool among patients from Ethiopia with esophagus and gastric cancer. Therefore, we recommend that researchers and clinicians use the core tool together with the specific tool.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.